Jennifer S Scherer1,2, Yingzhi Qian3, Megan E Rau2, Qandeel H Soomro4, Ryan Sullivan5, Janelle Linton2, Judy Zhong3, Joshua Chodosh2, David M Charytan4. 1. Division of Nephrology, Department of Internal Medicine, New York University Grossman School of Medicine, New York, New York Jennifer.scherer@nyulangone.org. 2. Division of Geriatric Medicine and Palliative Care, Department of Internal Medicine, New York University Grossman School of Medicine, New York, New York. 3. Division of Biostatistics, Department of Population Health, New York University Grossman School of Medicine, New York, New York. 4. Division of Nephrology, Department of Internal Medicine, New York University Grossman School of Medicine, New York, New York. 5. Division of Enterprise Data Warehouse & Analytics, Department of Medical Center Information Technology, New York University Langone Health, New York, New York.
Abstract
BACKGROUND AND OBJECTIVES: AKI is a common complication of coronavirus disease 2019 (COVID-19) and is associated with high mortality. Palliative care, a specialty that supports patients with serious illness, is valuable for these patients but is historically underutilized in AKI. The objectives of this paper are to describe the use of palliative care in patients with AKI and COVID-19 and their subsequent health care utilization. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective analysis of New York University Langone Health electronic health data of COVID-19 hospitalizations between March 2, 2020 and August 25, 2020. Regression models were used to examine characteristics associated with receiving a palliative care consult. RESULTS: Among patients with COVID-19 (n=4276; 40%), those with AKI (n=1310; 31%) were more likely than those without AKI (n=2966; 69%) to receive palliative care (AKI without KRT: adjusted odds ratio, 1.81; 95% confidence interval, 1.40 to 2.33; P<0.001; AKI with KRT: adjusted odds ratio, 2.45; 95% confidence interval, 1.52 to 3.97; P<0.001), even after controlling for markers of critical illness (admission to intensive care units, mechanical ventilation, or modified sequential organ failure assessment score); however, consults came significantly later (10 days from admission versus 5 days; P<0.001). Similarly, 66% of patients initiated on KRT received palliative care versus 37% (P<0.001) of those with AKI not receiving KRT, and timing was also later (12 days from admission versus 9 days; P=0.002). Despite greater use of palliative care, patients with AKI had a significantly longer length of stay, more intensive care unit admissions, and more use of mechanical ventilation. Those with AKI did have a higher frequency of discharges to inpatient hospice (6% versus 3%) and change in code status (34% versus 7%) than those without AKI. CONCLUSIONS: Palliative care was utilized more frequently for patients with AKI and COVID-19 than historically reported in AKI. Despite high mortality, consultation occurred late in the hospital course and was not associated with reduced initiation of life-sustaining interventions. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_02_24_CJN11030821.mp3.
BACKGROUND AND OBJECTIVES: AKI is a common complication of coronavirus disease 2019 (COVID-19) and is associated with high mortality. Palliative care, a specialty that supports patients with serious illness, is valuable for these patients but is historically underutilized in AKI. The objectives of this paper are to describe the use of palliative care in patients with AKI and COVID-19 and their subsequent health care utilization. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective analysis of New York University Langone Health electronic health data of COVID-19 hospitalizations between March 2, 2020 and August 25, 2020. Regression models were used to examine characteristics associated with receiving a palliative care consult. RESULTS: Among patients with COVID-19 (n=4276; 40%), those with AKI (n=1310; 31%) were more likely than those without AKI (n=2966; 69%) to receive palliative care (AKI without KRT: adjusted odds ratio, 1.81; 95% confidence interval, 1.40 to 2.33; P<0.001; AKI with KRT: adjusted odds ratio, 2.45; 95% confidence interval, 1.52 to 3.97; P<0.001), even after controlling for markers of critical illness (admission to intensive care units, mechanical ventilation, or modified sequential organ failure assessment score); however, consults came significantly later (10 days from admission versus 5 days; P<0.001). Similarly, 66% of patients initiated on KRT received palliative care versus 37% (P<0.001) of those with AKI not receiving KRT, and timing was also later (12 days from admission versus 9 days; P=0.002). Despite greater use of palliative care, patients with AKI had a significantly longer length of stay, more intensive care unit admissions, and more use of mechanical ventilation. Those with AKI did have a higher frequency of discharges to inpatient hospice (6% versus 3%) and change in code status (34% versus 7%) than those without AKI. CONCLUSIONS: Palliative care was utilized more frequently for patients with AKI and COVID-19 than historically reported in AKI. Despite high mortality, consultation occurred late in the hospital course and was not associated with reduced initiation of life-sustaining interventions. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_02_24_CJN11030821.mp3.
Authors: David S Goldfarb; Judith A Benstein; Olga Zhdanova; Elizabeth Hammer; Clay A Block; Nina J Caplin; Nathan Thompson; David M Charytan Journal: Clin J Am Soc Nephrol Date: 2020-04-28 Impact factor: 8.237
Authors: Kelly Chong; Samuel A Silver; Jin Long; Yuanchao Zheng; V Shane Pankratz; Mark L Unruh; Glenn M Chertow Journal: Clin J Am Soc Nephrol Date: 2017-10-17 Impact factor: 8.237
Authors: Ravindra L Mehta; Maria T Pascual; Sharon Soroko; Brandon R Savage; Jonathan Himmelfarb; T Alp Ikizler; Emil P Paganini; Glenn M Chertow Journal: Kidney Int Date: 2004-10 Impact factor: 10.612
Authors: Glenn Gade; Ingrid Venohr; Douglas Conner; Kathleen McGrady; Jeffrey Beane; Robert H Richardson; Marilyn P Williams; Marcia Liberson; Mark Blum; Richard Della Penna Journal: J Palliat Med Date: 2008-03 Impact factor: 2.947
Authors: Derek Moriyama; Jennifer S Scherer; Ryan Sullivan; Joseph Lowy; Jeffrey T Berger Journal: J Pain Symptom Manage Date: 2021-01-05 Impact factor: 3.612
Authors: Jia H Ng; Jamie S Hirsch; Azzour Hazzan; Rimda Wanchoo; Hitesh H Shah; Deepa A Malieckal; Daniel W Ross; Purva Sharma; Vipulbhai Sakhiya; Steven Fishbane; Kenar D Jhaveri Journal: Am J Kidney Dis Date: 2020-09-19 Impact factor: 8.860
Authors: Greet De Vlieger; Eric Hoste; Hannah Schaubroeck; Wim Vandenberghe; Willem Boer; Eva Boonen; Bram Dewulf; Camille Bourgeois; Jasperina Dubois; Alexander Dumoulin; Tom Fivez; Jan Gunst; Greet Hermans; Piet Lormans; Philippe Meersseman; Dieter Mesotten; Björn Stessel; Marc Vanhoof Journal: Crit Care Date: 2022-07-25 Impact factor: 19.334